Gyre Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update
Provided By GlobeNewswire
Last update: May 9, 2025
SAN DIEGO, May 09, 2025 (GLOBE NEWSWIRE) -- Gyre Therapeutics (“Gyre”) (Nasdaq: GYRE), an innovative, commercial-stage biotechnology company focused on organ fibrosis, today announced financial results for the first quarter ended March 31, 2025 and provided a business update.
Read more at globenewswire.com
